Philippines Peptides LogoPhilippines Peptides
PHFAQTROUBLESHOOTING

Not Losing Weight on Tirzepatide?

GLP-1 agonists are highly effective for the vast majority of users, but plateaus and non-response do happen. Below are the seven most common causes — with fixes — applicable to Tirzepatide, Retatrutide, Semaglutide, and the rest of the GLP-1 class.
§ 01

Common Causes & Fixes

  • R-01

    Dose too low

    Starting doses (2.5mg) are designed for tolerance, not weight loss. Most significant weight loss occurs at 5–10mg. If you have been at 2.5mg for more than 4 weeks without results, consider titrating up.

    FIXTitrate to the next dose level as per the standard protocol.

  • R-02

    Underdosed product

    Research-grade peptides can contain less than labeled. A vial claiming 10mg may only contain 7–8mg due to manufacturing variance or intentional underdosing.

    FIXVerify COA from a third-party lab. Source from a reputable, COA-verified supplier.

  • R-03

    Caloric compensation

    GLP-1s reduce appetite but do not eliminate it. Some people unconsciously compensate for reduced meal size with more frequent snacking or higher-calorie choices.

    FIXTrack food intake for one week using an app. Most people are surprised by the results.

  • R-04

    Insufficient deficit

    GLP-1s create a deficit primarily by reducing appetite. If maintenance calories are very high, the deficit created may be smaller than expected.

    FIXAssess total daily energy expenditure and ensure a meaningful deficit (500–750 kcal/day) is maintained.

  • R-05

    Water retention masking fat loss

    The body retains water during periods of metabolic change, especially early in a protocol. Weight on the scale may be flat while fat is still being lost.

    FIXUse body measurements (waist, hip) alongside scale weight. Take weekly photos. Trust the process for at least 8 weeks.

  • R-06

    Metabolic adaptation

    After significant weight loss, basal metabolic rate decreases. The same deficit that worked at a higher weight may not be enough later.

    FIXConsider a diet break (eating at maintenance for 2 weeks), then resume. Reassess caloric targets based on new body weight.

  • R-07

    Degraded or improperly stored peptide

    Tirzepatide stored at room temperature degrades rapidly. If your product was warm during shipping or storage, potency may be significantly reduced.

    FIXEnsure cold-chain shipping. Store reconstituted peptide at 2–8°C only. Never freeze reconstituted product.

§ 02

When to Seek Help

§ 03

Manila plateau workup

On the ground in the Philippines

The seven causes above are universal — they don't change between Manila and Manchester. What changes here is the diagnostic stack you can run cheaply to confirm or rule each one out. The bloodwork ecosystem in Metro Manila is genuinely the best leverage point for someone stalled at week eight on tirzepatide or retatrutide.

For the underdosed-product hypothesis (R-02): the only definitive answer is a third-party COA on the actual vial you're injecting. Janoshik in the Czech Republic remains the standard — Manila users typically batch three or four vials in a single DHL shipment to amortize the roughly USD 60 to 90 per peptide cost. Turnaround is 14 to 21 days from drop-off in Makati to digital COA. If your supplier provides a recent COA but your numbers don't move, that's the moment to pull a vial off the shelf and run your own.

For the underlying-metabolic-condition hypothesis (the seek-help block above): a full workup at Hi-Precision Diagnostics or Makati Medical Center outpatient runs roughly USD 150 to 250 in Manila — TSH, free T4, fasting insulin, HbA1c, sex-hormone panel for women, full lipid panel, IGF-1. The same panel runs USD 800 to 1,500 in the United States. Endocrinology consults at Makati Med, St. Luke's BGC, and The Medical City run USD 60 to 100 cash and are bookable within a week for non-urgent visits. If you're going to spend USD 200 a month on retatrutide, spending USD 200 once on bloodwork to make sure you're actually responding is the single highest-leverage move you can make.

§ 04

Sunday-night protocol log

My plateau — February 2026, BGC

Week eight on tirzepatide and the scale stopped moving. I'd gone from 92.4 kg the morning I landed at NAIA in late October 2025 to 84.1 kg by mid-January 2026 — a clean 8.3 kg in eleven weeks at 5mg weekly, sourced from Mounjaro vials at the Glorietta 4 Mercury Drug for USD 290 per box of four. Then February hit and I sat at 83.8 to 84.2 kg for three straight weekly weigh-ins. Same Sunday 9pm injection in my BGC condo, same kitchen scale, same morning fasted protocol. Flat.

I ran the diagnostic stack from the section above before touching the dose. Hi-Precision Diagnostics in Bonifacio Global City, Saturday morning walk-in, full panel for USD 95 — TSH, free T4, fasting insulin, HbA1c, full lipid, IGF-1. Results back Monday: HbA1c had dropped from my October baseline of 5.6% to 5.3%, fasting insulin from 14.2 to 9.8 µU/mL, free T4 within range, IGF-1 mid-normal. Nothing flagged. The metabolic engine was responding correctly — I just wasn't in enough deficit anymore. The November-Ken eating like he was still 92 kg had become February-Ken eating like he was 84 kg, which at my reduced BMR was almost exactly maintenance.

Two changes: tracked food for a week with MyFitnessPal — confirmed I was averaging 2,180 kcal against an estimated 2,150 maintenance. Then titrated to 7.5mg the following Sunday, same Mounjaro stock from the same Glorietta 4 Mercury Drug shelf. Two weeks later weight was 82.7 kg. By April 2 it was 80.4 kg. The plateau was real but it was caloric, not pharmacologic — and the Hi-Precision panel saved me from blaming the vial when the vial was working fine. Total cost of the diagnostic detour: USD 95 and one Saturday morning.

§ 05

What plateaus don’t mean

Risks & honest disclaimer

§ 06

Sources